BOSTON, April 22, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan.

Cycle Pharmaceuticals (Cycle) has launched Cycle Vita PKU, an AI-powered app to help patients with PKU manage every aspect of their treatment plan. It can be challenging for patients with PKU ...

Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...

Cambridge-headquartered Pragmatic Semiconductor has appointed ... Steve has held senior roles at Cycle Pharmaceuticals, Antalis and CP Kelco. He has led and scaled high-growth businesses ...

Most recently, McCue was CFO at Cambridge-based pharmaceutical scale-up Cycle Pharmaceuticals. He has also served as group CFO at Antalis and held leadership roles at **** Kelco and AVEX Electronics.

Cycle Pharmaceuticals, Inc. (Cycle) announces today completion of the acquisition of Banner Life Sciences, LLC (Banner) which includes its BAFIERTAM (monomethyl fumarate) product for the treatment ...

One of the most strategic moves a pharmaceutical company can make is to establish an evidence generation plan (EGP) early in the asset life cycle—ideally around phase one. While much attention ...

A woman raped at knifepoint in the Cambridgepark office complex in May sued the ... of the building at 125 Cambridgepark Drive, Cambridge,” the lawyers wrote. They added that there are ...

Urges Vanda Shareholders to Express Their Views on the Proposal to the Independent Directors of the Vanda Board of Directors Boston, MA & Cambridge, U.K. – October 14, 2024 – Cycle Pharmaceuticals Ltd ...

(Reuters) -Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda (NASDAQ:VNDA)'s ...

Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is ...